MYC (MYC proto-oncogene, bHLH transcription factor), LNX1, YBX1, FN1, TK1 and ANLN (anillin actin binding protein) are likely to provide new potential biomarkers for clinical practice or treatment of T1DM with further research. This evidence concerns the gene ANLN and type 1 diabetes mellitus.